SCHEDULE: Principal Global Investors Amends Collegium Stake
Beneficial Ownership Report
Principal Global Investors has updated its beneficial ownership in Collegium Pharmaceutical, Inc., reporting a 4.6% stake as of June 30, 2025.
Summary
- Principal Global Investors filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Collegium Pharmaceutical, Inc.
- As of June 30, 2025, Principal Global Investors beneficially owns 1,466,506 shares of Collegium Pharmaceutical, Inc. common stock.
- This ownership represents 4.6% of the total class of securities.
- Principal Global Investors holds shared voting power and shared dispositive power over all 1,466,506 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine disclosure of beneficial ownership by an institutional investor, indicating a passive stake. It does not contain information that would significantly alter the perceived value or performance of the company.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding institutional ownership, confirming a significant but passive stake by Principal Global Investors.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring filing, representing the beneficial ownership stake. |
| 08/08/2025 | Date of filing and signature by Principal Global Investors. |
Keywords
Collegium Pharmaceutical, Principal Global Investors, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.